Recommendation for Appropriate Use of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure
Circ J
.
2023 Oct 25;87(11):1707-1709.
doi: 10.1253/circj.CJ-23-0605.
Epub 2023 Sep 22.
Authors
Atsushi Tanaka
1
,
Koichiro Kinugawa
2
,
Koichiro Kuwahara
3
,
Hiroshi Ito
4
,
Toyoaki Murohara
5
,
Ken-Ichi Hirata
6
,
Koichi Node
1
;
administrative board members of the Japanese Circulation Society and the Japanese Heart Failure Society
Affiliations
1
Department of Cardiovascular Medicine, Saga University.
2
Second Department of Internal Medicine, University of Toyama.
3
Department of Cardiovascular Medicine, Shinshu University School of Medicine.
4
Department of General Internal Medicine 3, Kawasaki Medical School.
5
Department of Cardiology, Nagoya University Graduate School of Medicine.
6
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
PMID:
37743518
DOI:
10.1253/circj.CJ-23-0605
No abstract available
MeSH terms
Canagliflozin
Heart Failure* / drug therapy
Humans
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Substances
Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin